Meditation is unusual among the practices in this programme in that it has been subjected to more rigorous clinical research than almost any other behavioural intervention of comparable simplicity. Over 12,000 peer-reviewed studies have examined its effects on human health, with hundreds of randomised controlled trials and multiple large meta-analyses commissioned independently by national health bodies. This is a genuinely well-evidenced practice — not a wellness-industry folk remedy with scattered supportive studies, but an intervention with a serious clinical evidence base spanning more than four decades. That said, the evidence is not uniformly strong across every claim made for meditation. Some areas — stress reduction, blood pressure, depression relapse prevention — have robust evidence from well-controlled trials. Other areas — cellular ageing, longevity, specific cognitive enhancements — have promising but less definitive evidence. And some popular claims circulating in the wellness space have little or no serious research support at all. Our reading of the evidence tries to be honest about each of these.This section walks through the evidence in seven areas: stress and anxiety, cardiovascular health, sleep, attention and cognition, mood and depression, adverse effects, and cellular ageing. At the end we name what the research does not show — an editorial choice that matters, because the meditation-adjacent marketplace is full of claims that outrun the science.
Before the individual areas, one important framing note. Most meditation research has been done on mindfulness-based approaches — techniques that trace back to the Mindfulness-Based Stress Reduction (MBSR) programme developed by Jon Kabat-Zinnat the University of Massachusetts in the late 1970s.¹ MBSR is an eight-week structured programme, typically involving 20 to 30 hours of instruction plus daily home practice, originally designed to help chronic pain patients. It has since become the most rigorously-studied meditation intervention in clinical research.
When meta-analyses talk about "meditation" they are usually, in practice, talking about MBSR or closely related mindfulness-based interventions. Other traditions — transcendental meditation, loving-kindness meditation, various contemplative practices from specific religious traditions— have their own research bases, some stronger than others, but the bulk of the high-quality evidence sits with mindfulness. This matters because if a member is drawn to a different style of practice, the evidence we summarise below will apply to them only indirectly. Most of it should transfer — the mechanisms appear to be largely shared across contemplative traditions — but the specific effect sizes and clinical findings are strongest for the mindfulness-based approaches.
Stress and anxiety are the areas where the evidence for meditation is strongest, and where the practice is most commonly recommended. The 2014 JAMA Internal Medicine meta-analysis mentioned in section 1 — commissioned independently by the US Agency for Healthcare Research and Quality, conducted by researchers at Johns Hopkins — examined 47 randomised controlled trials of meditation programmes and concluded that mindfulness meditation produces moderate reductions in anxiety, depression, and psychological distress across diverse adult populations.² These effects were comparable to those reported for other evidence-based psychological interventions. Subsequent meta-analyses over the past decade have confirmed and extended these findings.
The mechanism here is relatively well understood. Regular meditation practice appears to reduce activity in the brain's default mode network (the neural circuitry associated with mind-wandering and self-referential thought, which is over-active in anxiety and depression) and to strengthen prefrontal regulation of the amygdala (the brain region central to the stress response). These neurobiological changes show up on imaging within weeks of consistent practice and correlate with the clinical improvements that members report. Clinical caveat: meditation is not a replacement for evidence-based treatment of diagnosed anxiety disorders or major depression. For those conditions, the evidence supports meditation as a useful component of a broader treatment approach — typically alongside cognitive behavioural therapy or medication — rather than as a stand-alone alternative. For sub-clinical stress and everyday anxiety, the evidence is considerably more direct.
The cardiovascular evidence for meditation is among the most surprising to members encountering it for the first time. Multiple meta-analyses have now shown that regular meditation practice produces measurable reductions in blood pressure — typically in therange of 4 to 6 mm Hg systolic and 2 to 4 mm Hg diastolic across mindfulness-based interventions.³ These are not large reductions in absolute terms, but they are clinically meaningful. At a population level, a 5 mm Hg reduction in systolic blood pressure translates to roughly a 10% lower risk of major cardiovascular events — heart attacks, strokes, cardiovascular death. The 2020 Hypertension journal meta-analysis by Lee and colleagues pulled together randomised controlled trials of MBSR specifically in patients with elevated blood pressure or hypertension, and confirmed significant reductions in office blood pressure — roughly 6.6 mm Hg systolic and 2.5 mm Hg diastolic at post-intervention, with the diastolic reduction sustained at three to six months.⁴ An important caveat from this same meta-analysis: the effects were clearly significant for office blood pressure measurements but did not reach significance for 24-hour ambulatory blood pressure monitoring.
This is a real limitation. Office BP is what most clinical trials have used as an outcome, and it is the primary target of most hypertension treatment guidelines, but 24-hour ambulatory BP is generally considered a more reliable predictor of cardiovascular risk. The honest reading is that meditation produces a real reduction in the BP readings that matter for clinical care, but whether this translates fully into 24-hour BP control is still being worked out. A more recent large randomised trial, the Mindfulness-Based Blood Pressure Reduction (MB-BP) study from Brown University, showed 4.5 mm Hg reductions in systolic blood pressure at six months in participants with elevated baseline pressure — outperforming the enhanced usual-care control group.⁵ The programme used in that trial wasadapted from MBSR specifically for hypertensive patients, with additional components focused on diet, physical activity, and medication adherence. This is worth noting: the clinical effect may come partly from the meditation practice itself and partly from the behavioural changes the practice supports (better eating, better sleep, better adherence to medication). Both mechanisms are welcome. Clinical caveat: the BP reductions produced by meditation are real but modest, and they should not be interpreted as a reason to discontinue prescribed antihypertensive medication. For members already on BP medication, meditation may help reduce the dose needed over time — but this must be managed with their GP, not unilaterally.
Meditation and sleep have a reasonable but nuanced evidence relationship, particularly for members with insomnia or sleep disturbance. A 2019 meta-analysis by Rusch and colleagues in the Annals of the New York Academy of Sciences examined 18 randomised controlled trials of mindfulness meditation for sleep quality, involving over 1,600 participants.⁶ The more precise reading of this meta-analysis is important: mindfulness meditation produced significant improvements in sleep quality compared to wait-list and inactive controls, but produced no significant difference when compared head-to-head against specific evidence-based sleep treatments including cognitive behavioural therapy for insomnia (CBT-I).
In other words, meditation and CBT-I produced similar sleep improvements — which makes meditation a reasonable alternative where CBT-I is not easily accessible, but does not establish meditation as superior to the standard psychological treatment for chronic insomnia. The practical implication for members: if sleep is the primary concern, CBT-I remains the first-line evidence-based psychological intervention and is available through the NHS. Meditation practice is a reasonable complementary or alternative approach, particularly where CBT-I waitlists are long or the member is already drawn to meditation for other reasons.
NSDR — short for Non-Sleep Deep Rest — is a term popularised by Stanford neuroscientist Andrew Huberman to describe yoga-nidra-style guided practices that produce a state of deep physiological rest while the practitioner remains awake. The practice is not new: yoga nidra has existed in contemplative traditions for centuries, and the body-scan elements of MBSR draw on similar principles. What is newer is the packaging of these practices as short, accessible, freely-available guided audio tracks that members can use without any prior training. The evidence base for NSDR specifically is smaller than the evidence base for seated meditation, but the physiological mechanisms overlap substantially. NSDR practices engage the parasympathetic nervous system (the "rest and digest" branch of the autonomic nervous system), reduce cortisol, and appear to help with both sleep onset at bedtime and mid-afternoon recovery when used during the day.
For members who find seated meditation difficult — who struggle with restlessness,i ntrusive thoughts, or physical discomfort in a still posture — NSDR offers an alternative entry point. It is done lying down, follows a guided voice, and requires no particular skill or experience. Our practical view: NSDR is a genuinely useful complement to meditation practice, particularly for members who want a wind-down tool for the end of the day or a recovery tool for mid-afternoon energy dips. Free guided NSDR audio is available at hubermanlab.com/nsdr, including a straightforward 10-minute version at hubermanlab.com/10-min-nsdr. It is not a replacement for the consistent daily seated practice that produces the effects discussed elsewhere in this section, but it is a useful adjunct and a reasonable gateway for members intimidated by more formal meditation.
Meditation is, at its core, a training of attention — so it would be surprising if sustained practice did not affect attentional function. The research base here is smaller than for stressor blood pressure but still reasonable. Meta-analyses have shown improvements in several specific attentional measures: sustained attention (the ability to focus on a single task for extended periods), selective attention (the ability to focus on relevant stimuli while ignoring distractions), and executive control (the ability to switch between tasks and resist impulses).⁷ The effectsare modest but reproducible.
For older adults, there is suggestive evidence that regular meditation practice may slow some age-related cognitive decline. Studies comparing long-term meditators with age-matched controls have found smaller age-related reductions in grey matter volume in several brain regions, better working memory performance, and better executive function.⁸ These are observational comparisons with all the usual caveats —people who choose to meditate regularly may differ from those who do not in ways that affect cognitive ageing independently — but the findings are consistent across multiple research groups. Clinical caveat: meditation is not a treatment for dementia or mild cognitive impairment. The evidence supports it as part of a broader brain-healthy lifestyle — alongside physical exercise, social engagement, and cognitive stimulation — rather than as a specific intervention for established cognitive decline.
The relationship between meditation and mood is among the most important — and most carefully studied —areas of the evidence base. For mild to moderate depression, meditation interventions produce reductions in depressive symptoms that are clinically meaningful, though typically smaller than those produced by either cognitive behavioural therapy or antidepressant medication in direct comparison trials.⁹ Mindfulness-Based Cognitive Therapy (MBCT) — a specific adaptation of MBSR developed to prevent depression relapse — has the strongest and most replicated evidence in this area.¹⁰ MBCT is now recommended by the UK's National Institute for Health and Care Excellence (NICE) as a prevention strategy for members who have had three or more prior depressive episodes.
The Kuyken 2016 individual patient data meta-analysis — which pooled data from nine randomised trials covering 1,258 patients — found that MBCT reduced the risk of depressive relapse by approximately 31% over 60 weeks compared to usual care, with comparable results versus active treatments including maintenance antidepressant medication. For a non-pharmacological intervention delivered over eight weeks, this is a substantial effect. Clinical caveat: for members with active major depression, meditation practice alone is not an adequate treatment. The evidence supports MBCT as a prevention strategy for relapse inthose who have recovered from previous episodes, and as an adjunct to other treatment for those in active depression. Members with current depressive symptoms should consult their GP about appropriate treatment.
The most biologically interesting area of the meditation evidence base — and the most directly relevant to Forever Well's longevity framing — sits at the cellular level. The story starts with a discovery that won Elizabeth Blackburn, Carol Greider, and Jack Szostak the 2009 Nobel Prize in Physiology or Medicine: the identification of telomeres (protective DNA caps at the ends of chromosomes) and the enzyme telomerase (which maintains them).
The essence of the biology, in plain English: every time a cell divides, its telomeres get a little shorter. Telomerase can add length back, but its activity declines with age and underchronic stress. When telomeres become critically short, cells can no longer divide properly — they enter a state of senescence and stop functioning well, or they die. The length of your telomeres is, in part, a measure of how much cellular ageing you have already accumulated. People with shorter telomeres tend to develop age-related diseases earlier and die younger. In 2004, Elissa Epel (a psychologist at UCSF) and Blackburn published a paper in the Proceedings of the National Academy of Sciences that was genuinely startling at the time. They studied 58 healthy pre-menopausal women — half of them mothers of chronically ill children (a population exposed to years of unrelenting care giving stress), half of them mothers of healthy children (matched controls). The caregiving mothers had significantly shorter telomeres and lower telomerase activity than the controls, and the effect was dose-dependent: the more years a woman had spent caregiving, and the higher her perceived stress, the shorter her telomeres.¹²
The striking headline from the accompanying commentary by neurobiologist Robert Sapolsky: the most-stressed women in the study had telomeres shorter by the equivalent of nine to seventeen years of accelerated cellular ageing.This was the paper that established, for the first time with cellular-level evidence, that psychological stress does not just make you feel bad — it measurably accelerates the process by which your cells age. The implication reaches beyond stress research. If chronic stress accelerates cellular ageing through oxidative damage and suppressed telomerase activity, then anything that reduces chronic stress should, in principle, slow that acceleration. This is where meditation enters the biological-ageing conversation.
Telomeres are one mechanism linking stress to ageing at the cellular level. Chronic low-grade inflammation is the other — and this is an area where the meditation evidence is actually clearer and more replicable than the telomere evidence. Researchers now use the term "inflammaging" to describe the low-level chronic inflammation that accumulates with age and drives most of the common age-related diseases: cardiovascular disease, type 2 diabetes, neurodegenerative disorders, and many cancers. The inflammatory markers that matter here have names that will be familiar to anyone who has had blood workdone: interleukin-6 (IL-6), tumour necrosis factor alpha (TNF-α), and C-reactive protein (CRP). Elevated levels of these markers predict worse long-term health outcomes independently of almost any other risk factor.
A 2016 randomised controlled trial by David Creswell's group at Carnegie Mellon found that three days of intensive mindfulness meditation training reduced IL-6 in high-stress unemployed adults more than an active relaxation control did, with the inflammatory reduction statistically mediated by measurable changes in brain network connectivity.¹⁵ At the population level, a large 2025 meta-analysis of 89 studies on mindfulness-based interventions and inflammatory markers found consistent reductions across the main inflammatory cytokines — moderate effect sizes for IL-6, TNF-α, and CRP, along with improvements in arterial stiffness.¹⁶ The inflammation-reduction mechanism appears to be more robust and more replicable than the telomere mechanism, probably because inflammatory markers respond more quickly to behavioural interventions and canbe measured with greater precision than telomere length can.
The practical takeaway for members: the cellular evidence does not establish that meditation will add years to your life in any specific quantified way. What it does establish is that daily meditation is probably working on the same biological ageing mechanisms that Forever Well's other pillars target — chronic inflammation, cellular stress, oxidative damage, and hormonal dysregulation. Blackburn and Epel's 2017 book The Telomere Effect is the accessible synthesis of this research programme, and we recommend it as a starting point for members who want to understand the biology in more depth.¹⁷
